Inhibition of motility by NEO100 through the calpain-1/RhoA pathway.
CONCLUSIONS: NEO100 could have significant value targeting GSCs and could be used for GBM therapy as either monotherapy or a coadjuvant therapy during temozolomide rest cycles.
PMID: 31419797 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - Category: Neurosurgery Authors: Marín-Ramos NI, Pérez-Hernández M, Tam A, Swenson SD, Cho HY, Thein TZ, Hofman FM, Chen TC Tags: J Neurosurg Source Type: research
More News: Alcoholism | Brain | Brain Cancers | Brain Tumor | Calcium | Chemotherapy | Gastroschisis Repair | Glioma | Neurology | Neurosurgery | Stem Cell Therapy | Stem Cells | Study | Temodar